Amezalpat

Small molecule

Also known as TPST-1120

On holdsponsor decision

Evidence outlook · program status

On hold, as a strategic decision by the sponsor

Tempest Therapeutics reports that its amezalpat programme is currently paused. The trials below are the program's evidence history; no evidence signal is assigned while development is paused.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Hepatocellular Carcinoma
Phase 1/2 (1)
Other / comorbidity
NCT04524871 · Hoffmann-La Roche
2020-11-01 – 2027-09-30 · Advanced Liver Cancers
What this study did
Phase 1 (1)
Hepatocellular Carcinoma
NCT03829436 · Tempest Therapeutics
2019-03-20 – 2022-09-07 · Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
What this study did

Competitive landscape

This drug's own stage for Hepatocellular Carcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Amezalpat: this drugPhase 3Small moleculePPARα (peroxisome proliferator-activated receptor alpha)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
CabozantinibApprovedSmall moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT01908426: Overall Survival (OS) (Up to 45 months): Cabozantinib (XL184) 10.2 months (95% CI 9.1 to 12) | Placebo 8 months (95% CI 6.8 to 9.4)
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT03062358: Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1)
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT02435433: Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Ramucirumab + Best Supportive Care (BSC) 8.51 Months (95% CI 7 to 10.58) | Placebo + BSC 7.29 Months (95% CI 5.42 to 9.07)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signalNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2not yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 3Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
JS207Phase 3Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
NamodenosonPhase 3—Adenosine A3 receptornot yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 3Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
PegargiminasePhase 3Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminasenot yet gradedNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
RYZ801Phase 1/2Radiopharmaceutical—not yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
SENTI-301APhase 1Cell therapyGPC3 (CAR-NK, calibrated IL-15)not yet gradedNo reviewed efficacy summary in this indication
SHR-2524Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
AZD7003
—(overall)
Cell therapyGlypican-3 (GPC3)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Development is on hold (source ↗). ClinicalTrials.gov still lists the estimated primary-completion dates below; they may not read out as listed.

2027 (1)
July 2027 (1)
Phase 1/2Advanced Liver CancersActive not recruitingProgramme on hold
Est. primary completion 2027-07-30 · NCT04524871 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 3Hepatocellular CarcinomaNot yet recruitingProgramme on hold
Est. primary completion 2028-12 · NCT06680258 · CT.gov ↗
What to watch

See the full readout calendar ↗